SCHEMBL5108906

SCHEMBL5108906

OCc1cnccc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 4/20 0.48
KCNA5 P22460 4/20 0.47
KCNH2 Q12809 2/20 0.47
RPS6KA3 P51812 2/20 0.47
CYP1A2 P05177 3/20 0.46
CYP2E1 P05181 3/20 0.46
CYP3A4 P08684 3/20 0.46
CYP2C8 P10632 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2A6 P11509 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2B6 P20813 3/20 0.46
CYP2C19 P33261 3/20 0.46
TNF P01375 1/20 0.46
GAA P10253 1/20 0.45
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
NOTUM Q6P988 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1769946 0.84 CYP11B2 (0.53) KCNA5KCNH2RPS6KA3CYP1A2CYP2E1
SCHEMBL13212635 0.82 DPP4 (0.59) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL14927060 0.82 CCNC (0.51) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL14927055 0.82 PTGS1 (0.47) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL3820660 0.81 RPS6KA3 (0.44) GPBAR1RPS6KA3NOTUMCYP11B1CYP11B2
SCHEMBL9336643 0.81 RPS6KA3 (0.53) RPS6KA3CYP11B1CYP11B2
Bromide SCHEMBL29018736 0.81 CCNC (0.50) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL21803764 0.81 CYP11B1 (0.55) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL1082101 0.79 GPBAR1 (0.42) GPBAR1KCNA5KCNH2RPS6KA3CYP1A2
SCHEMBL477395 0.78 KCNA5 (0.61) KCNA5KCNH2CYP1A2CYP3A4CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937055-B2 Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-20 US disclosed
US-20130296276-A2 HETEROCYCLIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-07 US disclosed
US-20130116214-A1 HETEROCYCLIC RING COMPOUND UJIKAWA OSAMU (JP) 2013-05-09 US disclosed
US-7342116-B2 Process for producing heterocyclic aldehyde KOEI CHEMICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20050124807-A1 oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound KOEI CHEMICAL CO., LTD. (JP) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124807-A1 oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound ADH1C, ADH1A, AOX1 GPBAR1 2266/4885KCNA5 2665/4885KCNH2 1144/4885
US-20130116214-A1 HETEROCYCLIC RING COMPOUND FABP4, CPT1B, GPR119 GPBAR1 295/4885KCNA5 3340/4885KCNH2 3722/4885
US-20130296276-A2 HETEROCYCLIC RING COMPOUND FABP4, CPT1B, GPR119 GPBAR1 295/4885KCNA5 3340/4885KCNH2 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.